N. A. Vaulin

  • Citations Per Year
Learn More
PURPOSE To compare lipid lowering profile and effects on markers of inflammation of rosuvastatin and fenofibrate in patients with type 2 diabetes with low high density lipoprotein (HDL) cholesterol (CH). METHODS We enrolled into randomized open comparative study 30 pts (20 women) aged 62.5 +/- 7.2 (47-74) years with type 2 diabetes and low HDLCH level(More)
AIM To study changes of left ventricular function and some markers of inflammation during use of simvastatin in patients with ischemic systolic heart failure. METHODS Statin naive patients (n=70) with coronary heart disease (CHD), NYHA class II-IV HF and LV ejection fraction (EF) 35% or less after 1 month of stabilization were randomized to simvastatin 40(More)
Effect of statins on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients with heart failure has not been well elucidated. Purpose. To assess changes of NT-proBNP during short term use of simvastatin in patients with coronary heart disease (CHD) and chronic systolic heart failure. Patients and methods. Statin naive patients (n=70) with coronary(More)
UNLABELLED It is not known whether PPAR-alpha agonist gemfibrozil is able to exert rapidly its lipid modulating, potential antiinflammatory and antithrombotic effects in patients with non-ST elevation acute coronary syndrome (NSTEACS), as some other lipid lowering drugs e.g. statins do. METHODS We randomized 44 patients with NSTEACS to open gemfibrozil(More)
AIM To find out whether early use of atorvastatin and pravastatin in patients with non-ST elevation acute coronary syndrome is associated with rapid changes of platelet aggregation and plasma levels of markers of inflammation. MATERIAL AND METHODS Ninety patients (<24h from pain onset, age 64+/-10 years) treated with aspirin and heparin were randomized to(More)
We present the results of the study of lipid-modulating drugs (pravastatin, atorvastatin, simvastatin, and fibrate gemfibrozil) in complicated coronary heart disease (acute coronary syndrome without ST elevation, chronic heart failure. In acute coronary syndrome statins produced a positive effect on some studied parameters, while in heart failure only the(More)
UNLABELLED Data on rapid effects of statins in patients (pts) with acute coronary syndrome (ACS) are mostly from trials of atorvastatin (ATO). We hypothesized that due to high potency 10 mg of rosuvastatin (ROS) would produce same changes of lipids and inflammation markers as 40 mg ATO. METHODS We openly randomized 53 pts (69.7+/-10.1 years, 58.5% - man)(More)
AIM To analyze relationship between changes of lipid levels and parameters of hemostasis and inflammation in a previously reported comparative study of some biological effects of pravastatin and atorvastatin in patients with non ST elevation acute coronary syndrome (NSTEACS). METHODS Ninety aspirin and heparin treated patients with NSTEACS were randomized(More)
PURPOSE To find out whether pravastatin and atorvastatin rapidly (in 1-2 weeks) and similarly affect hemostasis in patients with non-ST elevation acute coronary syndrome (NSTEACS). METHODS Ninety aspirin and heparin treated patients with NSTEACS were randomized <24 hours from pain onset to open pravastatin 40 mg/day (n=31), atorvastatin 10 mg/day (n=30)(More)
  • 1